ABBV vs MRK — Key Metrics

Metric ABBV (ABBVIE INC) MRK (MERCK & CO INC)
Price286.01137.78
Market Cap505.56 Billion339.66 Billion
P/E (TTM)49.06137.78
P/B (Quarterly)-109.2358.257
P/S (TTM)7.665.04
Net Profit Margin (TTM)15.73.6
Gross Margin (TTM)73.771.8
ROE (TTM)-201.05.3
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

ABBVIE INC
vs
 
MERCK & CO INC
 
ABBVIE INC
vs
 
MERCK & CO INC
Performance Comparison
AI Model Recommendation
ABBV · ABBVIE INC

Outperform

44
UnderperformOutperform
MRK · MERCK & CO INC

Greatly Outperform

82
UnderperformOutperform
Recommendation Summary

Stock ABBV is projected to outperform the market, stock MRK is projected to greatly outperform the market. Upfront Recommendation: MRK.

Financial Metrics
Prices delayed ~15 min
ABBV Metrics MRK
$286.01 Price $137.78
— Market Capitalization —
49.06 Price to Earnings Ratio 137.78
7.66 Price to Sales 5.04
26.79 Price to FCF Ratio 23.03
10.39 Price to Gross Profit 7.03
50.75 Price to R&D 11.04
13.49 Price to Current Assets 8.72

ABBV vs MRK at a glance

Abbvie INC (ABBV) and Merck & CO INC (MRK) are both Drug Manufacturers - General companies in the Healthcare sector. ABBV is the larger, at $505.6 billion in market value against $339.7 billion for MRK, about 1.5 times the size.

On trailing-twelve-month figures, ABBV trades at 49.1 times trailing earnings and MRK at 137.8; net profit margins are 15.7% and 3.6%.

The Upfront Investment model currently rates ABBV Outperform and MRK Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.